Safety and Efficacy of Disease-Modifying Anti-Rheumatic Agents: Focus on the Benefits and Risks of Etanercept

ISSN： 0114-5916

Source： Drug Safety, Vol.25, Iss.3, 2002-01, pp. : 173-197

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Safety and efficacy of disease-modifying antirheumatic agents in rheumatoid arthritis and juvenile rheumatoid arthritis

By Fleischmann Roy

Expert Opinion on Drug Safety, Vol. 2, Iss. 4, 2003-07 ,pp. : 347-365

Informa Healthcare

Access to resources Recommend Favorite

Efficacy, Tolerability and Cost Effectiveness of Disease-Modifying Antirheumatic Drugs and Biologic Agents in Rheumatoid Arthritis

By Nurmohamed Michael T. Dijkmans Ben A.C.

Drugs, Vol. 65, Iss. 5, 2005-01 ,pp. : 661-694

Adis International

Access to resources Recommend Favorite

Monitoring and Assessing the Safety of Disease-Modifying Antirheumatic Drugs: A West Midlands Experience

By Jobanputra P. Maggs F. Homer D. Bevan J.

Drug Safety, Vol. 25, Iss. 15, 2002-01 ,pp. : 1099-1105

Adis International

Access to resources Recommend Favorite

Defining Juvenile Idiopathic Arthritis Remission and Optimum Time for Disease-Modifying Anti-Rheumatic Drug Withdrawal: Why We Need a Consensus

By Broughton Thomas

Pediatric Drugs, Vol. 14, Iss. 1, 2012-02 ,pp. : 7-12

Adis International

Access to resources Recommend Favorite

Effects of Biologic Agents and Other Disease-Modifying Antirheumatic Drugs on Cardiovascular Outcomes in Psoriasis and Psoriatic Arthritis: A Systematic Review

Current Pharmaceutical Design, Vol. 20, Iss. 4, 2014-02 ,pp. : 500-512

Bentham Science Publishers

Access to resources Recommend Favorite